Image_2_SP1/AKT/FOXO3 Signaling Is Involved in miR-362-3p-Mediated Inhibition of Cell-Cycle Pathway and EMT Progression in Renal Cell Carcinoma.TIF
Emerging evidence has indicated that dysregulation of miR-362-3p is involved in the initiation and progression of several types of human cancers. However, the molecular mechanism of miR-362-3p in renal cell carcinoma (RCC) is still not completely clear. In this study, we found that miR-362-3p was frequently down-regulated in human RCC tissues. Overexpression of miR-362-3p in RCC cells significantly suppressed the proliferation, cell cycle and motility in vitro and in vivo via regulating AKT/FOXO3 signaling. We further confirmed that SP1 was a direct target of miR-362-3p. Knockdown of SP1 expression by a small interfering RNA (siRNA) phenocopied the effect of miR-362-3p overexpression in RCC cells. In conclusion, the current results provide evidence for the role of miR-362-3p in the pathogenesis of RCC and thus miR-362-3p may serve as an attractive candidate for RCC therapy.
History
References
- https://doi.org//10.21873/cgp.20147
- https://doi.org//10.1016/s0092-8674(04)00045-5
- https://doi.org//10.1111/febs.13148
- https://doi.org//10.1016/j.eururo.2018.08.036
- https://doi.org//10.1016/j.canlet.2012.01.027
- https://doi.org//10.1002/ijc.28010
- https://doi.org//10.1038/nrg2634
- https://doi.org//10.1002/ijc.29210
- https://doi.org//10.1038/cdd.2015.116
- https://doi.org//10.1093/carcin/bgs336
- https://doi.org//10.1186/s12943-017-0664-1
- https://doi.org//10.1186/s12943-018-0856-3
- https://doi.org//10.1158/1078-0432.ccr-13-1687
- https://doi.org//10.1002/jcb.25110
- https://doi.org//10.3322/caac.21442
- https://doi.org//10.1016/j.pharmthera.2015.05.008
- https://doi.org//10.1186/s12943-018-0766-4
- https://doi.org//10.3892/ol.2016.4953
- https://doi.org//10.1007/s10059-013-0044-7
- https://doi.org//10.1186/1476-4598-13-109
- https://doi.org//10.1080/15384101.2018.1557490
- https://doi.org//10.1186/s12967-014-0222-1
- https://doi.org//10.1007/s10620-015-3563-6
